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Hepatitis C (HCV-RNA) genome in the serum of renal transplant patients
with 11CV Ab: comparison with a population of hemodialysis patients. M.
Adorati, C. Pipan, G.A. Botta, P. Collinassi, C. Vallone, P. Messa, R.
Franzon, and G. Mioni, Department of IVephrology, Department of
Immunohaematology and Transfusion, Udine General Hospital, Institute
of Microbiology, University Hospital, Udine, Italy. Fourteen renal trans-
plant patients of 82.5 61 months and 22 chronic dialyzed patients whose
results were HCV-Ab positive from the second generation ELISA test,
confirmed by the second generation RIBA test, were examined for viral
genome in serum by the polymerase chain reaction technique (PCR) using
primers from the 5' non-coding region (UTR), highly preserved in all the
strains isolated so far. All the transplant patients with HCV-Ab had
previously been on HD for 64 89 months and subjected to pre-transpiant
transfusions. Viral genome was isolated in 10/14 transplant patients (71%),
a significantly higher percentage than that found in other groups or noted
by us among the HCV-Ab positive hemodialysis patients (50%). InS out of
the 10 positive PCR patients, high ALT values (129—59 U/liter) were
repeatedly found, while no movements of hepatocytic enzymes were
observed in the four negative PCR cases. Among the dialyzed patients, on
the other hand, no correlation was found between ALT and HCV-RNA
positivity. The antibody profile in both populations examined was not
correlated to the presence of viral genome in the serum or to ALT values.
During checks carried out after a year, Ab anti-HCV was seen to have
disappeared in 2 of the negative PCR, but not in any of the positive PCR
cases. In conclusion, in the case of Ab anti-HCV positivity, HCV-RNA
was found more frequently in transplant patients than in hemodialysis
patients; only in the former was viral presence correlated to hepatocytic
damage. In this category of patients, testing for HCV-RNA thus appears
more important in the clinical study of subjects with Ab anti-HCV.
T cell immunity and its variations after 1,25-dihydroxyvitainin 1)3 i.v. in
uremic patients with secondary hyperparathyroidism. D. Angelini, A.
Carlini, R. Giusti, L. Mazzotta, R. Grassi, E. Mei, I. Fiorini, and A.
Antonelli, Departments of Nephrology, Analysis, and Endocrinology,
Hospital of Lucca, Lucca, Italy. In this study we evaluated the changes of
T lymphocytes in dialysis patients with secondary hyperparathyroidism,
after therapy with I ,25-dihydroxyvitamin D3 [I ,25(OH)2D3} iv. We stud-
ied 11 patients (7F and 4M) aged between 29-70 years, with parathyroid
hormone (PTH) of 749.9 pg/mI 431.2. They received 1 ug of
1 ,25(OH)2D1 i.v. at the end of dialysis for 3 months and later 2 g for the
other 9 months. We evaluated intact PTH, total T lymphocytes, CD4,
CD8, CD4/CD8 ratio, calcemia, and osteocalcin at the beginning and at the
end of the study. Our results are expressed in the table as mean SD.
PTH T Lymph CD4
pg/mi %
Baseline 749.9 431.2 65.5 2.8 36.8 4.3
After 3 months 796.7 646.2 70.8 4.1 40.7 6.1
After 12 months 407.3 296.2 70.2 2.9 40.0 3.4
Controls 45.6 29.2 75 7 45 JO
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CD8 % CD4/CD8
Baseline 31.9 5.3 1.17 0.33
After 3 months 28.0 3.9 3.50 0.40
After 12 months 28.1 0.9 1.40 0.10
Controls 28 8 1.60 0.20
These results show a significant decrease of total T lymphocytes, CD4,
CD4/CD8 ratio, and a slight increase of CD8 compared to the controls
(P < 0.001, P < 0.01, P < 0.001, P < 0.1). We can't see significant
variations of PTH after the first 3 months of therapy with I ,25(OH)2D3
i.v., but after 12 months PTH decreases significantly (P < 0.008). There
was also an increase of osteocalcin after 3 months from 68.8 pg/mI 41
to 109.1 pg/mI 30(P <0.01), while it decreased after 12 months to 50
pg/mI 36.4 (P < 0.0001). There was an increase of total T lympho-
cytes after 3 months of therapy (P < 0.0002), an increase of CD4 (P <
0.08), and a significant decrease of CD8 (P < 0.05) with increment of
CD8/CD4 ratio (P < 0.04), without other significant changes after 12
months. We can conclude that the improvement of T cellular immunity
could be due to the direct action of I ,25(OH)2D3 on T cells indepen-
dently from the correction of the hyperparathyroidism.
Platelet malondialdehyde production, erythrocyte and platelet fatty
acid cell membrane composition in non-dialyzed and dialyzed uremic
patients. M. Azzini, D. Girelli, 0. Olivieri, P. Guarini, M.T. Trevisan,
A. Lupo, P. Bernich, G. Panzetta, and R. Corrocher, Institute of
Medical Pathology, Institute of Clinical Chemistry, Chair of Medical
Nephrology, University of Verona, Italy. The aim of this study was to
evaluate the erythrocyte (RBC) and platelet fatty acid (FA) membrane
composition in patients with chronic renal failure (CRF), with special
regard to the relationship with different dialytic procedures. Patients
were divided into three groups: l6 non-dialyzed, 16 undergoing hemo-
dialysis (HD), and 16 undergoing continuous ambulatory peritoneal
dialysis (CAPD). Forty-eight healthy subjects were considered as the
control group. Patients with diabetes mellitus, nephrotic syndrome or
any other condition that might influence lipid metabolism were ex-
cluded. The FA composition of cell membrane was measured by
gas-cromatography; in CRF patients we also analyzed platelet MDA
production after stimulation with thrombin as index of thromboxane A2
(powerful proaggregating and vasoconstrictor platelet mediator) forma-
tion. The comparison of FA membrane composition between CRF
patients (regardless of the type of treatment) and controls showed
important differences: the CRF patients had a significant increase in
RBC oleic acid (P < 0.001). The analysis of variance performed in the
three distinct groups of CRF patients showed a marked increase of the
arachidonic acid in HD (P < 0.001), while in CAPD group a further
increase of oleic acid (P < 0.00l) occurred. An accurate 7-day diet
history performed in all the CRF patients excluded influences due to
variations in FA dietary intake. Platelet membrane fatty acid composi-
tion showed similar differences, (increased arachidonic acid in HD
group), suggesting a "systemic" metabolic abnormality. The HD group
was also characterized by an increase in platelet MDA production (P <
0.01), a direct significant correlation between platelet arachidonic acid
level and MDA production was found in the whole population of CRF
patients. Our data reveal a FA metabolism alteration in CRF patients,
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conditioned by different dialysis procedures. The increased arachidonic
acid in HD patients might help to explain their platelet hyperaggrega-
bility and accelerated atherosclerosis.
VLA-3, the glomerular epithelial cell (GEC) th adhesion molecule,
presents an altered distribution pattern in membranous nephropathy. A.
Baraldi, L. Furci, D. Maccan, A. Di Felice, and E. Lusvarghi, Chair of
Nephrology, University of Modena, Italy. VLA (f3 integrins) are
heterodimeric (a/13) transmembrane glycoproteins connecting cytoskel-
eton F-actin microfilaments to the extracellular matrix proteins, thus
conditioning various cellular functions such as motility, adhesivity and
cell dimension and shape. Recently, a3f31 has been described as the sole
/3 integrin on GEC promoting adhesion between podocytes and a still
unrecognized ligand (laminin or fibronectin) on the glomerular base-
ment membrane (GBM). By means of an amplified immunofluorescence
(IF) technique (streptavidin-fluorescein), we investigated a3/3, in nor-
mal human kidneys as well as in 12 renal biopsy samples from patients
affected with nephrotic syndrome of different etiology: 2 minimal
change (MC), 8 membranous nephropathy (MN) in different stages
(I-Ill), and 2 class IV lupus nephritis (LN). In normal glomeruli a3f31
presents an intense brilliant, linear IF colocalized with laminin on
GBM. In MC no alteration was found, while in all cases of MN small,
round defects on the thickened, trabecular GBMs were well evident
since the 1st stage. In the 3rd stage of MN, wider segmental labeling
defects were evidenced on the capillary loops. In class IV LN linear
expression of a3f31 was preserved. Previously, many ultrastructural
studies have demonstrated focal detachments between podocytes and
GBM in Heymann's glomerulonephritis and, more recently, anti-adhe-
sive molecules have been found in the subepithelial space. Moreover,
an altered laminin production has been detected on MNGBM in close
proximity to immune deposits. We suggest that an altered adhesion of
podocyte foot processes could be present in MN.
Angiotensin U receptors and gene expression of the AT1 receptor in rats
with streptozotocin.lnduced diabetes mellitus. L.A. Sechi, C.A. Griffin,
E. Bartoli, and M. Schambelan, Division of Endocrinology, Depart-
ment of Medicine, University of Cal(fornia, San Francisco, USA, and
Department of Internal Medicine, University of Udine, Udine, Italy.
We previously reported that the density of angiotensin II (Ang II)
receptors is decreased in kidneys and increased in hearts of rats with
streptozotocin (STZ)-induced diabetes. In the present study we have
compared the expression of the gene for the AT1 receptor, the subtype
of more than 90% of renal and hepatic Ang II receptors, in tissues
obtained from streptozotocin (STZ)-diabetic rats (DIAB) and vehicle
treated controls (CONT). AT1 mRNA was significantly decreased in
kidney (8.1 0.4 vs. 11.7 0.5 scanner units) and liver (13.0 1.1 vs.
17.8 1.0 s.u.) of DIAB, mirroring changes in receptor density. No
difference in plasma renin concentration was found between CONT and
DIAB. In an additional experiment, subgroups of CONT and DIAB rats
were infused with Ang 11(200 ng/kg/min i.p. for 7 days) or saline (Sal).
Ang II receptors number (Bmax) and affinity (Kd) were evaluated by an
in situ autoradiographic technique; AT1 mRNA was measured by slot
blot hybridization with a 32P-labeled cRNA probe. Ang II infusion
significantly decreased plasma renin concentration and renal Ang II
receptors Bmax both in CONT (35.7 0,6 to 31.0 1.7 pmol/mm3
tissue, P < 0.05) and DIAB (22.9 1.0 to 9.3 0.8 pmol/mm3, P <
0.005) rats without a significant change in Ang II receptors Kd and AT1
mRNA steady-state levels, as shown below.
Group Kidney Liver
CONT + Sal 21.1 1.2 34.7 2.1
CONT + Ang II 23.7 0.8 35.9 1.0
DIAB + Sal 14.1 1.8k 20.5 l.5
DIAB + Ang II 14.7 o.sa 20.7 1.3k
Values are means 5EM and are expressed as scanner units.
Significantly different from the respective control.
Thus, this study demonstrates that a reduced AT1 gene expression
accounts for the reduced Ang II receptor number in the kidney of
STZ-diabetic rats. Chronic Ang II administration, while reducing Ang II
receptors number, does not change AT1 mRNA levels in the kidney of
control and diabetic rats. This indicates that Ang II down-regulates its
own renal receptors by a post-transcriptional mechanism or an in-
creased receptor turnover.
Regulation of collagen III (col ifi) expression by renal cells in vitro:
Cloning of the promoter of human col III gene and models of analysis. R.
Bertelli, R. Ravazzolo, G. Caridi, and G.M. Ghiggeri, Department of
Nephrology, G. Gaslini Institute, Genoa, and Department of Biology,
University of Genoa (I), Genoa, Italy. Col III is a major component of
extracellular matrix expansion in renal diseases, characterized by
glomerulosclerosis and/or interstitial fibrosis. Studies with renal cells in
vitro have shown that col III is up-regulated by soluble factors, such as
TGF and bFGF which are implicated in the pathogenesis of a few
experimental nephrites. To further extend the comprehension of the
mechanisms involved in the regulation of col III expression, we
amplified, by PCR, a region of 1433 bp containing the DNA sequence
immediate up- and downstream the start transcription site of col III
gene, utilizing the following primers: 5'TAGCACCATCAAGTTGT-
TCCC3' (from +41 to +61) and 5'GCAAG1TFGCCCACTGTCCATG3'
(from —1372 to —1352). Different segments of the same sequence were
obtained by PCR to localize possible regulating DNA binding sites to
specific transacting factors. The amplified genomic DNAs were se-
quenced and subcloned in two vectors with different reporter systems:
(a) one contained a CAT reporter (Chloramphenicol Acetyl Trans-
ferase/Cl4 chloramphenycol); and (b) the other was associated to
luciferase which converts luciferine into luciferyl-CoA with emission of
photons. Gene induction experiments employed 3T3 fibroblasts trans-
fected with recombinant plasmid DNA bearing the col III promoter
sequences. The sum of experiments indicated that the luciferase system
is by far the most sensitive and reproducible reporter for analyzing col
III promoter activity. The same level of promoter activity was observed
with the 3 subclones bearing different DNA portions, suggesting that
the regulatory binding site is located within the 350 bp of the smallest
nucleotide segment.
Endotoxins may modulate tumor necrosis factor alpha (TNFa) and
interleukin-6 (IL-6) release by monocytes (Mø) from uremic patients. D.
Bottalico, G. Pertosa, L. Gesualdo, and F.P. Schena, Chair and
Division of Nephrology, Dialysis and Traspiantation, Polyclinic, Ban,
Italy. Cytokines may be released during hemodialysis (HD) due to
complement activating dialysis membranes or microbial products in
dialysate. We examined the capacity of uremic MØ to release TNFa and
IL-6 upon stimulation with endotoxin (ET)-contaminated bicarbonate
(BC) concentrate. Seven patients underwent one-month subsequent
periods of HD (4 patients with cuprophane and 3 patients with polyac-
rilonitrile membranes), by using dialysate prepared with either BC
concentrate tanks (phase 1) or sterile BC concentrate bags (Clear-Flex,
Bieffe, Italy) (phase 2). After each period of treatment, MØ were
harvested before and after HD and cultured for 24 hours in RPM!.
TNFa and IL-6 concentrations were determined in supernatants by
ELISA. ET levels in BC concentrates were measured by a chromogenic
Limulus Amebocyte Lysate (LAL) assay. Results (mean SD) are
summarized below:
ET EU/mI
TNFa
pg/mi
pre-/post-HD
IL-6
pg/mi
pre-/post-HD
Phase I 0.153 0.034a 43.8 16.9/
60.2 370b
92.1 81.3/
175 121.5
Phase 2 0.035 0.012 22.8 13.4/
36.4 16.4
61.6 55.7/
63.3 39.90
P < 0.001 and bP < 0.02 vs. phase 2.
A significant increase in LAL reactivity was found in BC concentrate
tanks compared to sterile bags. With contaminated dialysate there was
a significant pre-HD increase in MØ TNFa release as compared to
controls (8.5 5.5 pg/mI). Under sterile dialysate conditions, TNFa
release decreased significantly as compared to phase 1, but it was still
higher than controls (P < 0.05). A similar decrease was observed for
IL-6 production, although the differences were not significant compared
to phase 1 and controls (73 40 pg/mI). HD treatment induced a further
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increase in both TNFa and IL-6 production, particularly in phase I. In
conclusion, TNFa and IL-6 release may be induced during HD with
ET-contaminated dialysate. These cytokines may, in turn, determine
pyrogenic and clinical adverse reactions in HD patients.
Muscle glycogen content and glycolytic activity in chronic renal failure
(CRF) on conservative treatment. G. Bovio, R. Aquilani, S. Segagni, M.
Dossena, P. Baiardi, 0. Pastoris, P. Foppa, and A. Salvadeo, Division
of Nephrology, Service of Nutrition Pathophysiology, Clinica del
Lavoro Foundation, IRCCS, Pavia; Institute of Pharmacology, Faculty
of Science, University of Pavia, Pavia, Italy. Impaired exercise toler-
ance has been described in CRF. As this is also influenced by muscle
glycogen content and glycolytic activity, we studied a possible modifi-
cation on these parameters at rest in CRF. A needle biopsy was
performed in the femoral quadriceps muscle of 16 fasting patients (II
males, 5 females; 56 II years) with CRF (creatinine 3.6 1.3 mg/dl)
and in 5 normal (N) subjects (59.7 3.5 years). In the muscle specimens
we determined: glycogen, glucose, glucose-6-phosphate, lactate, pyru-
vate, hexokinase (H K), phosphofructokinase (PFK), pyruvatekinase
(PK), and lactatedehydrogenase (LDH). No difference in metabolites
was observed between CRF and N, except in glycogen which was
significantly lower in CRF (29.8 24 smo1es of glycosidic units/g of
fresh tissue vs. 78 17; P < 0.001). Enzyme activities showed a
significant increase in HK (86 43 nmoles/min/mg of protein vs. 33.4
7; P < 0.01) and in LDH (2414 929 vs. 1538 499; P < 0.01); there
was a significant decrease in PK (957 140 vs. 1817 726; P < 0.01)
and no difference in PFK (135.6 45.5 vs. 132.6 36.4). We conclude
that in CRF there is a reduced muscle glycogen content, an increase in
glucose phosphorilation in fasting patients, and a decreased pyruvate
production deriving from glycolysis. These results could partly explain
the impaired exercise tolerance in CRF.
Role of endothelin and endothelium-derived relaxing factor in renal
microcirculation. A. Cavarape, E. Bartoli, E. Gulbins, J. Hoffend, and
M. Steinhausen, Department of Internal Medicine, University of
Udine, Udine, Italy; and I. Institute of Physiology, University of
Heidelberg, Heidelberg, Germany. In order to investigate the role of
endothelin (ET) and endothelium-derived relaxing factor (EDRF/NO)
on control of renal vascular tone under basal conditions, we have tested
the effects of intravenous infusion of polyclonal rabbit anti-human
ET-1/3 antibodies (a-ET-l/3) and competitive inhibitor of EDRF/NO
synthase N'-Nitro-L-arginine-methyl-ester (L-NAME) on the split
hydronephrotic kidney of rats. This preparation is the only model in
which most elements of the renal microcirculation can be directly
visualized in vivo, showing changes of vascular diameters and single
glomerular blood flow (GBF) in intravital microscopy. A 25 minute i.v.
infusion of a-ET-1/3 (4.8 lO mol kg' .min) induced a time-
dependent vasodilation of larger pre-glomerular vessels, pronounced in
distal arcuate (+ 16.5%) and proximal interlobular arteries (+ 18.6%).
The vasodilation induced an increase of GBF by 32% without effects on
systemic blood pressure. Inhibition of EDRF/NO synthesis by intrave-
nous infusion of the EDRF inhibitor L-NAME (2 mg kg) induced a
marked vasoconstriction of proximal (—17.1%) and distal (—7.1%)
arcuate arteries (—17.1%) as well as efferent arterioles (—20.1%), and a
decrease of GBF by 43%. A third series of experiments assessed
interactions between EDRF and ET: inhibition of both systems by
infusion of a-ET-l/3 followed after 10 minutes by a bolus injection of
L-NAME induced vasoconstriction of efferent arteriole by 19.5%,
whereas diameters of preglomerular vessels remained unchanged, prob-
ably because of additive effects of inhibitors. GBF decreased by 13%.
The specificity of a-ET-l/3 effects in our model has been tested and
confirmed by co-infusion of a-ET-1/3 and ET-l (160 ng), which pro-
duced no significant renovascular effects. Bolus injection of ET-l alone
(160 ng) constricted arcuate arteries. Injection of a-ET- 1/3 in normal rat
kidneys induced an increase of renal blood flow by 21%. The experi-
ments performed in this study localized vascular effects of ET-antago-
nists and EDRF-synthesis inhibitors in the in vivo model of hydrone-
phrotic kidney of rats. Our observations by direct intravital microscopy
with combined inhibition of ET effects and EDRF/NO synthesis suggest
a physiological role of EDRF and ET in control of basal vascular tone
in larger preglomerular vessels, whereas the tone of the efferent
arteriole appears to be predominantly regulated by the action of
EDRF/NO.
Sensitivity, specificity and accuracy of echo-doppler pulsatility index
for diagnosis of renal artery stenosis. M. Cianci, L. Burdick, F. Airoldi,
M. Giussani, A. Lovaria, S. Saccheri, A. Morganti, Clinica Medica and
Centro di Fisiologia Clinica e Ipertensione, UniversitO and Ospedale
Maggiore, Milano, Italy. Ultrasound techniques are widely used for
detection of renal artery stenosis (RAS), but the diagnostic accuracy of
the many indices proposed to achieve this aim is largely unknown. We
evaluated that of pulsatility index (FL), that is, the ratio between the
difference of maximum and minimum and mean flow velocity (Vmax —
V,,in/Vman), recording it with an ATL Ultramark 9 color echo-doppler(3 MHz sector mechanical probe) either at the renal hylum or in the
interlobar arteries in 35 patients, 8 of whom with essential hyperten-
sion, 24 with unilateral, and 3 with bilateral renal artery stenosis for a
total of 30 stenotic and 40 normal arteries; all these diagnoses were
angiographically proved. The optimal threshold of P1 for detecting RAS
was calculated from the receiver-operating characteristics (ROC) curve
obtained by the ratio between the true positive (TP) and the false
positive (FP) rates at different thresholds; by this method the ideal cut
off of P1 was set at 1.09. Using this discriminating value we found 28 TP,
24 true negative (TN), 15 FP and 3 false negative (FN) arteries; thus, the
sensitivity and specificity of P1 were respectively 90% and 61%. Yet if
the data of the two arteries were analyzed independently, the diagnosis
was incorrect in one or both arteries in 16 (46%) of patients. However,
if the difference (is) in P1 between the two arteries was considered we
found that with a i  0.23 eleven of 16 misdiagnoses were eliminated,
whereas two new errors were introduced: as a result only 7 (20%) of
patients were incorrectly diagnosed. Therefore, the evaluation of P1 in
a single artery, even at its optimal threshold, has a good sensitivity but
a lesser specificity in detecting RAS; however, by the combined
differential measurement of P1 the diagnostic accuracy of this index can
be raised to 80% of patients.
Evaluation of recipient sensitization versus donor alloantigens by flow
cytometric cross match in kidney transplantation. P. Cinti, A. Bachetoni,
V. Baiano, R. Pretagostini, L. Poli, M. Salpietro, E. Renna Molajoni,
and R. Cortesini, 11 Patologia Chirurgica Università La Sapienza,"
Roma, Italy. Over the past few years many reports have demonstrated
that flow cytometric cross match (FCXM) is a more sensitive technique
to detect clinically relevant antibodies that are missed by a complement
dependent cytotoxic cross match. The aim of this study was to analyze
the correlation between FCXM and the rejection course of transplanted
kidney. Materials and methods: From January to December 1992, 43
kidney transplant recipients [27 from living related donors (LRD) and 16
from living unrelated donors (LUD)I have been studied pre-Tx and
during the first three post-operative months. The FCXM was performed
as follows: donor lymphocytes were incubated with recipient serum,
fluorescein stained anti-human IgG and 1gM F(ab)2 immunoglobulin
(Kallestad) were added to identify the isotype of anti-lymphocytes
antibodies. The lecture was performed by Becton Dickinson FACScan.
Rejection episodes were confirmed by cytological, immunological and
clinical data. Treatment of acute rejection consisted of 6-MP 500 mg—I
g/day i.v. for three days or ALG administration. The extracorporeal
immunoabsorbition with staphilococcal protein A column (EXCORIM)
was employed in three 6MP and ALG resistant cases. The patients were
plasmaphered five times on alternate days. Results: All patients were
FCXM negative before transplant. During the first three post-operative
months, 24/43 patients suffered a rejection crisis, of which: 21/24 had a
reversible acute rejection 47.6% with negative FCXM, 33.3% with
positive FCXM <30%. 19.1% with positive FCXM between 30%—50%;
3/24 patients with positive FCXM > 50% developed a pharmacological
humoral resistant rejection. These patients were plasmapheresed and
monitorized by FCXM. In 2/3 patients a negative FCXM and a recovery
of graft function after extracorporeal immunoabsorbition was observed.
Conclusion: Our data pointed out that flow cytometric cross match is a
helpful method to evaluate the post-transplant antibody status in renal
transplant recipients. Moreover, the findings may have important
implications in the monitoring of subjects who underwent extracorpo-
real immunoabsorbition.
Elevated activity of L-type voltage dependent calcium (Ca2) channels
causes high intracellular Ca in vascular smooth muscle cells (VSMC) of
Milan hypertensive rats. M. Cirillo, M. Canessa, and N,G. De Saab,
Nephrology, Medical School of Naples, Second University, Naples,
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Italy; Endocrine-Hypertension Division, Harvard Medical School, Bos-
ton, USA. Cellular Ca2 transport was studied using 45Ca and Fura-2 in
aortic VSMC of 2-month-old genetically hypertensive (MHS) and
normotensive (MNS) rats. VSMC were cultured as previously de-
scribed and made quiescent before experiments by incubation in 0.3%
serum medium. Quiescent VSMC of MHS had higher cytosolic Ca2
concentration compared to MNS (+21.8%, P < 0.05). Exchangeable
Ca2 pool was similarly elevated in MHS (+23.8%, P < 0.001). Ca2
influx, measured by initial rate of 45Ca uptake, was elevated in MHS at
early and late culture passages (+25.9%, P = 0.005). The elevation was
due to high activity of nifedipine- (N if, 1 M) sensitive channels, while
the Nif-resistant Ca2 influx was similar in MHS and MNS cells. Ca2
efliux, in VSMC preloaded with 43Ca, was measured as rate constant
using a double compartment exponential model: this value was not
different between MHS and MNS. The results indicate that elevated
activity of Nif-sensitive (L-type) Ca2 channels accounts for high
cytosolic Ca2* in quiescent VSMC of MHS. This alteration could be
pathogenetically relevant to the Milan model of rat hypertension
considering the role of cellular Ca2 in VSMC contraction and the
antihypertensive effect of Ca2* channel blockers.
Effects of erythropoletln on spontaneous histamine release in whole
blood in hemodialysis patients. S. De Marchi, E. Cecchin, G. Sepiacci,
D. Villalta, G. Santini, and E. Bartoli, Department of Internal Medi-
cine, University of Udine Medical School; Department of Immunology,
General Hospital, Pordenone, italy. Enhanced levels of plasma hista-
mine are reported in uremic patients. The aims of this study were to
measure spontaneous histamine release (SHReI) in whole blood and
plasma histamine concentration (pHis) of uremic patients on mainte-
nance hemodialysis, and to investigate the changes in these parameters
that occurred during erythropoietin (rHuEpo) therapy. A randomized
and placebo controlled study was undertaken in 22 hemodialysis
patients. Thirty healthy subjects provided blood samples for measure-
ments of SHReI and pHis. Hemodialysis patients were randomly
assigned to receive rHuEpo (N = 11) or placebo (N = II) for 2 weeks,
and were followed for 4 weeks. Erythropoietin (30 units/kg body wt)
was administered i.v., thrice weekly, at the end of a dialysis treatment.
SHReI and pHis were measured before and at the end of the period of
therapy, and one and two weeks after the discontinuation of rHuEpo.
Blood samples were taken before dialysis. Hemodialysis patients had
higher values of SHReI (6.3 0.5 vs. 2.4 0.4%; P < 0.01) and pHis
(6.5 0.6 vs. 2.2 0.7 nmollliter; P < 0.01) compared to healthy
subjects. Erythropoietin therapy induced a fall in SHReI and pHis (P <
0.01). At the end of the treatment there was no difference in SHrel and
pHis levels between hemodialysis patients and healthy subjects. SHReI
and pHis increased again after the discontinuation of rHuEpo. Conclu-
sions: Uremic patients receiving maintenance hemodialysis have en-
hanced spontaneous histamine release in whole blood that may contrib-
ute to the elevated plasma histamine levels. Erythropoietin therapy
results in a marked decrease of spontaneous histamine release and
plasma histamine concentration.
Gluconic acid (GA) as glucose substitute in peritoneal dialysis. N. Di
Paolo, G. Garosi, A. Guarnieri, E. Gaggiotti, and M. Di Paolo,
Division of Nephrology, Siena, Italy. In the present study we evaluated
the biocompatibility of the following dialysis solutions: (I) lactate buffer
(LB), glucose; (2) LB, GA; (3) bicarbonate buffer (BB), glucose. The
following parameters were evaluated at different concentrations of
dialysis liquid: (a) growth of mesothelial cells in culture; (b) levels of
LDH, IL-I, IL-2 receptor and a-TNF in mesothelial cell culture
supernatant; (c) toxicity to mesothelial cells (optical and transmission
electron microscope studies); (d) mesothelial cell secretion of phospho-
lipids, phosphatidylcholine, LDH, 6-keto-PGF-l and PGE2. Cell
growth was better in solutions with BB than in those with LB. and was
completely absent in solutions with GA. In solutions with RB and
glucose, levels of IL-I were much lower and levels of phospholipids,
phosphatidylcholine, PGF-l and PGE2 much greater than in the other
two solutions. Microscope study showed fewer toxic effects in solutions
with BB. Solutions containing RB have much better biocompatibility
than those with LB. It will be interesting to test solutions with BB and
GA.
Biocompatlbility of peritoneal dialysis solutions with bicarbonate buffer
(BB). N. Di Paolo, G. Garosi, A. Guarnieri, E. Gaggiotti, and M. Di
Paolo, Division of Nephrology, Siena, Italy, In the present study we
evaluated the biocompatibility of four dialysis solutions: (1) BB, 1.5%
glucose; (2) BB, 4.25% glucose; (3) lactate buffer (LB) 1.5% glucose; (4)
LB, 4.25% glucose. The following parameters were evaluated at differ-
ent concentrations of dialysis liquid: (a) growth of mesothelial cells in
culture; (b) levels of LDH, IL-I, IL-2 receptor and a-TNF in mesothe-
hal cell culture supernatant; (c) toxicity to mesothelial cells (optical and
transmission electron microscope studies); (d) mesothelial cell secre-
tion of phospholipids, phosphatidylcholine, LDH, 6-keto-PGF-l and
PGE2; (e) guinea pig microcirculation in vivo. In solutions with BB,
mesothelial cells grew better and showed fewer signs of toxicity in the
microscope studies; phospholipid and phosphatidylcholine secretion
were greater and that of IL-I less. In solution with lactate, capillary
vasodilatation was greater. These results show that dialysis solutions
buffered with bicarbonate have better biocompatibility than those
buffered with lactate.
Polymethylmethacrylate (PMMA) dialysis does not reduce ICAM-1 and
LFA-1 expression on peripheral blood leukocytes (PBLs). C. Esposito, G.
Fuiano, A. Caglioti, M.M. Mauro, M. Rosa, N. Comi, M. Gullo, M.
Capria, and A. Dal Canton, Departments of Nephrology, University of
Catanzaro and Pa via, and Division of Nephrology, Crotone, Italy.
Recently, it has been shown that cuprophan dialysis down-regulates the
expression of adhesion molecules on peripheral blood leukocytes. This
unfavorable effect for the already depressed uremic immune system
may be blunted by a more biocompatible dialysis membrane. To
address this possibility, we studied the effects of PMMA in three uremic
patients formerly on regular cuprophan dialysis. After three weeks of
PMMA dialysis blood samples were drawn before and after a dialysis
session. The expression of adhesion molecules ICAM-l, LFA-l, CD44
and other leukocyte determinants were then studied by flow cytometry
using specific monoclonal antibodies. Unlike cuprophan dialysis mem-
brane, PMMA increases rather than reduces the expression of ICAM-1
and LFA-l. Concerning CD44 and the other leukocyte determinants,
down-regulated by cuprophan dialysis, no changes were observed. Our
data confirm PMMA biocompatibility and suggest that PMMA dialysis
should be the first choice dialysis in particularly immunodepressed
uremic patients.
Arterial pressure (AP) and peritoneal (PERIT) clearances. A. Favazza,
D. Montanaro, R. Franzon, P. Messa, G. Boscutti, and G. Mioni,
Renal Unit, Regional Hospital, Udine, Italy. Since we have noticed a
significant correlation between AP and PERIT clearances (Cl), we
compared PERIT transport in 34 CAPD patients (pats) with mean
arterial pressure (MAP) 110 mm Hg (C-pats) to 28 CAPD pats with
MAP > 110 mm Hg (H-pats), whose hypotensive therapy was sus-
pended for 8 days. The 2 groups were comparable for nephropathy, age
(C = 65 10; H = 61 II years) and CAPD duration (C = 21.3 20;
H = 20.9 19 months). All 62 pats underwent a 4 hour exchange using
2.27 g/dl glucose 2 liter bag. The following parameters were analyzed:
net ultrafiltration (UF); effluent/initial dialysate glucose ratio (OL D/Do);
PERIT Cl (mum') of BUN, K, creatinine (Cr), P-, Beta2microglobulin
(/32m), albumin (AIb), transfemn (Tran), G-immunoglobuhin (IgO);
total proteins (PRO) [mg/4 hr) and Na removal; residual diuresis (ml/24
hr).
The other parameters were statistically similar. Moreover, the 2 groups
were different in the hematocrit (C-pats = 32.5 5; H-pats = 29.7
4.9; P < 0.05). In addition, in all 62 pats the plasmatic PRO was
significantly correlated with GL 1)/Do (r = 0.431; P = 0.000), Cr-Cl (r
—0.369; P = 0.001), $2m-Cl (r = —0.376; P = 0.001), Alb-Cl (r =
—0.283; P= 0.03), tran-CI (r = —0.29; P = 0.03) and IgG-Cl (r = —0.31;
GL D/Do m-Cl
C-pats 40.8 6.2 0.892 0.29
H-pats 37.0 5.8k 1.122 0.34a
lgG-Cl
PRO-
removal
P < 0.05; H-pats vs. C-pats.
0.0526 0.025
0,0767 0.05k
1466 579
1890 87l
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P = 0.019). On the contrary, there was no correlation between
plasmatic PRO and UF. Twelve H-pats have subsequently undergone a
re-evaluation of PERIT function after a stable decrease of body weight
at an average of 5.5%, by means of hemodialytic or PERIT ultrafiltra-
tion. MAP was reduced from 118 12 to 105 16mm Hg(P = 0.004),
UF from 600 241 to 508 261 ml/4 hr (P = 0.2). Cr-Cl was reduced
by 12.2% (P = 0.002), K-Cl by 7.5% (P = 0.03), j32m Cl by 17.1% (P =
0.024), AIb-CI by 23.6% (P = 0.03), lgG-C1 by 40.4% (P = 0.007),
residual diuresis (10 pats) by 31.1% (P = 0.04), while UL D/Do was
increased by 12.5% (P = 0.04). These observations confirm that sodium
and volume expansion have primary importance in the pathogenesis of
hypertension in CAPD pats. Furthermore, the volume balance consid-
erably affects PERIT transport of small and large molecular weight
solutes, and residual diuresis.
Mechanisms of the preventive activity of glycosaminoglycans on exper-
imental diabetic nephropathy. G. Gambaro, A.P. Vent urini, A.
Brunello, M. Vincenti, W. Fries, D. Noonan, G. Bertaglia, E. Marchi,
and B. Baggio, Institute of Internal Medicine, University of Padova;
National Cancer Institute, Genova; Alfa Wassermann SpA, Research
Division, Bologna, Italy. Chronic administration of glycosaminoglycans(GAGs) had favorable effect on experimental diabetic nephropathy
preventing albuminuna, GBM thickening and the reduction of GBM
anionic charge density. This study was carried out to understand
molecular mechanisms of the favorable GAG effects. Three groups of
male Sprague-Dawley rats were studied: controls (C), and 2 groups of
streptozotocin diabetic animals, (STZ and FMH), one of which was
treated chronically with a fast moving heparin heparin (FMH) s.c.
Follow-up was of 12 months. At 5 months in some animals the in vivo
35Sulfate glomerular incorporation was determined (autoradiography).
At 12 months we evaluated: albuminuria, anionic and neutral dextran
clearances, GBM thickness, GBM anionic charge density, in vitro
mRNA hybridization for type LV collagen and the heparan-sulfate
proteoglycan (perlecan) in renal cortex. GBM thickness was 460 12
nm (mean SEM) in C, 536 22 in STZ, and 420 24 in FMH (F =
6.75; P = 0.023). GBM charge density was 39.4 2.5 points/l000 nm,
32.3 1.2 in STZ and 54.2 2.5 in FMH (F = 5.8; P = 0.033).
Albuminuria was 20.9 7.5 mg/day in C, 116.0 31.9 in STZ, and 38.8
9.0 in FMH (F = 4.44; P = 0.019). While anionic dextran clearance
profile was compromised in STZ rats, in FMH it was normal. "Sulfate
glomerular incorporation was 620 32 silver grains/m2 in C, 195 49
in STZ and 355 24 in FMH (F = 4.02; P = 0.034). Type IV collagen
mRNA levels expressed in optical density unit per g of total RNA
were 0.540 0.216 in C, 0.766 0.154 in STZ, and 0.501 0.123 in
FMH (F = 3.69; P = 0.042). Perlecan gene expression was slightly
reduced in both diabetic groups. This study confirms our previous data
demonstrating that the long-term administration of GAGs has a favor-
able effect on morphological and functional renal abnormalities in
diabetic rats most likely modifying GBM/matrix composition.
Insulin receptor gene expression in liver and kidney of spontaneously
hypertensive (SHR) and Dahl salt-sensitive (DS) rats. L.A. Sechi, C.A.
Gr/fin, G. Sechi, and E. Bartoli, Department of Internal Medicine,
University of (Jdine, Udine, Italy, and Division of Endocrinology,
Department of Medicine, University of California, San Francisco,
California, USA, Insulin resistance and hypennsulinemia are present in
essential hypertensive patients and might be involved in the pathophys-
iology of this disease. Insulin resistance and hyperinsulinemia are
present also in some strains of rats with genetic hypertension, such as
spontaneously hypertensive (SHR) and DahI salt-sensitive (DS) rats. To
determine whether these abnormalities are mediated at the level of
insulin receptor (IR) gene expression, we compared JR mRNA levels in
SHR and DS rats, and in their respective normotensive controls
Wistar-Kyoto (WKY) and DahI salt-resistant (DR) rats. Since we have
previously reported that IR mRNA is decreased in kidneys of Sprague-
Dawley rats fed high-salt diets, rats were fed either low- (LS: 0.07%
NaCI) or high-salt (HS: 7.5% NaCI) chow until the SHR and DS became
hypertensive (4 weeks) and then were killed by decapitation. JR mRNA
levels were quantitated by slot blot hybridization using a c-RNA probe.
Liver Kidney
Groups LS HS LS HS
WKY 4.71 0.47 3.38 0,26b 2.12 0.07 1.79 0.lo
SHR 343 Ø47 3.34 0.24 1.89 0.12 1.89 0.09
DSR 3.11 0.56 3.89 0.23 1.80 0.12 1.83 0.05
DSS 2.82 0.38 3.11 0.45 2.11 0.15 1.93 0.10
Values are means SEM and are expressed as scanner units. a p <
0.05, b P < 0.025 vs. WKY-LS.
Hepatic JR mRNA levels were significantly (P < 0.05) lower in SHR
than in WKY fed LS, whereas in the kidney no difference was observed
between SHR and WHY. HS diet decreased significantly JR mRNA
steady-state levels in both liver and kidney of WKY but not of SHR. IR
mRNA values were comparable in both liver and kidney of DR and DS
rats fed either LS or HS. Thus, a decreased IR gene expression in the
liver of SHR provides a potential explanation for the insulin resistance
present in these rats. Moreover, SHR rats lost the possibility to
down-regulate IR mRNA when fed high-salt containing diet. Other
mechanisms should be considered to explain insulin resistance in Dahi
hypertensive rats.
Spondylo-epiphyseal dysplasia tarda (SED-T) and nephrotic syndrome
(NS). G. Lama, N. Marrone, A.M. Aurino, M. Mayorana, and MM.
Rinaldi, Dipartimento di Pediatria 2 Universitâ, Servizio di Genetica,
Ospedale Cardarelli, Napoli, Italy. Glomerular abnormalities and skel-
etal dysplasia are not commonly associated. Recently, the association
between SED and focal glomerular sclerosis has described in three
boys; the NS led to end-stage renal failure in all patients. We report the
data of three siblings that presented morphologic and skeletal signs of
SED-T associated with NS. They have sanguineous (I cousin) healthy
parents. Case I: boy, born in 1968, birth weight 2500 g. At the age of 8
years, he was admitted to the hospital for edema; a nephrotic syndrome
was diagnosed which did not respond to a 5-week course of daily
prednisone; renal biopsy revealed mesangiocapillary glomerulonephri-
tis (MCGN). Combined therapy with cyclophosphamide and PDN were
of no benefit; he developed hypertension and progressive renal failure
(end-stage RF after 4 years). The patient died from a complication after
two months of hemodialysis. At the age of II years his height was 122
cm (<3° thc —3.2 so); his trunk was short. Case II: boy, born in 1965,
birth weight 2600 g. At the age of 12 years, a 24 hour urinary sample
revealed non-nephrotic proteinuria confirmed in successive analysis;
after 3 years proteinuna increased (55 mg/kg/day) with normal serum
protein. His family refused to do other investigations and at 22 years old
he was admitted to the hospital with end-stage RF. He was hemodia-
lyzed a few months until his mother donated a kidney. Five years after
renal transplantation, renal function is normal and proteinuria is absent.
At the age of 22 years his height was 158cm (<3°thc), the same as at IS
y; the trunk is short, the thoracic cage is increased in anteroposterior
diameters; skeletal X-rays shows lombar and vertebral platyspondyly.
Case III: girl, born in 1978, birth weight 2500 g. From birth to 12 years
old the pts was free of problems. At 12.5 years was admitted to hospital
for pain and restricted mobility of the right hip. X-rays showed deep
acetabuli and short femoral necks, mild dysplastic changes especially in
right hip. Skeletal X-rays: dorsal and lombar platyspondyly. In the last
two years she had dramatic failure of statural growth (cm 142.2 <3 thc);
laboratory demonstrated only mild proteinuria with normal serum
protein and normal renal function. After the esclusion of other specific
metabolic, endocrine, immunological, genetic disorders we diagnosed
the rare association of SED-T and NS; the mode of inheritance is
compatible with an autosomal recessive disorder.
Soluble interleukin-2 receptor (IL-2R) levels in the serum and synovial
fluid of uremic patients with dialysis amyloidosis (DA). T. Lusenti, R.
Rustichelli, F. Soliani, and P.P. Borgatti, Nephrology and Dialysis
Division, S. Maria Nuova Hospital, Reggio Emilia, Italy. The higher
mean C-reactive protein plasma levels in uremic patients with amyloid
arthropathy (AA) and dialysis amyloid presented as acute arthritis,
leading some authors to believe that inflammatory reactions are primary
in the pathogenesis of DA. We investigated 6 chronic uremic patients on
long-term hemodialysis, 4 by cuprophane membrane and 2 by cellulose
acetate hemodiafiltration, with clinical signs of DA (CTS, bilateral
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popliteal cysts, shoulder effusive arthropathy, Guyon's syndrome).
Alter physical examination, we measured, by aspiration of one of the
involved joints, the pre-dialytic concentrations of /32-microglobulin
(132m) and IL-2R in paired samples of serum (S) and synovial fluid (SF).
None of the patients presented flogistic articular signs. Mean 32m (P <
0.05) and IL-2R (P < 0.001) levels resulted higher in S than in SF, and
in all the samples, the S/SF ratio was > I. Moreover, the increased
mean IL-2R S values were no different between these 6 patients with
DA and 36 dialysis patients with no joint symptoms. As with J32m,
increased IL-2R serum levels do not differentiate between patients with
or without DA. Moreover, in contrast to a typical flogistic arthropathy
such as rheumatoid arthritis, IL-2R and 132m levels lower in SF than in
S suggest the diffusion from blood to SF through the synovial mem-
brane, rather than a primary local immune-mediated arthropathy.
Nevertheless, the subclinical immunological processes related to re-
peated dialysis treatment, stimulating the release of cytokines and
proteases, could determine an alternative /32m proteolysis which,
producing 2m fragments, increases f32m amyloidogenesis.
How and how long to store urine samples for enzymic assays: A 1
year-study on five urinary enzymes. E. Matteucci, C. Uncini-Manga-
nelli, M. Cecere, F. Ruberti, C. Bertoni, and 0. Giampietro, Istituto di
Clinica Medica ii, Scuola di Specializzazione in Patologia Clinica,
Universitd degli Studi di Pisa, Pisa, Italy. Measurement of urinary
enzymes is currently employed as non-invasive test of renal integrity in
clinical nephrology. The evaluation of urinary enzyme implies some
practical difficulties because of an unusual medium such as urine for
enzymic assays. For five urinary enzymes (Gamma-glutamyl-transpep-
tidase, GGT, lactate dehydrogenase, LDH, and alkaline phosphatase,
AP, in 30 control individuals; Alanine aminopeptidase, AAP, and
N-acetyl-p-D-glucosaminidase, NAG, only in 15 healthy controls) we
checked time and temperature stability during sample collection and
storage before assay. Enzymic activities were measured on the same
urine samples, centrifuged (c) or not (nc): soon after collection, after 24
hour storage at 20 or 4°C and serially during storage at —20 or —70°C
starting from the first week to 1 year extent, when necessary. We
demonstrated that: (I) short-term storage at 20 or 4°C does not affect
enzyme activities in urine and specimen centrifugation is not crucial; (2)
GOT, AP and LDH are extremely labile at low temperatures (both —20
and —70°C): enzymic activities decrease to negligible values within one
month, the decrease starting already after one day of freezing. Follow-
ing one month both at —20 and —70°C, AP decreased until 50% of the
basal value, LDH to 9%. Alter one month at —20°C, the recovered GGT
was about 10% of the basal value. After the same period, only in the
centrifuged urines and at —70°C, GOT is partly preserved (55% of the
baseline). (3) AAP fell to about 8% in unnes I month frozen at —20°C;
it is quite stable (99% of the basal value) at —70°C, both on c and nc
samples, as long as 1 year at least. (4) NAG is unchanged after 1 month
at —20 and —70°C. After 12 months of storage, NAG is still preserved
at —70°C (84%), significantly decreased at —20°C (50%). Conclusions:
(1) urinary GOT, LDH and AP need to be assayed as soon as possible.
If there is a delay in analysis, urine can stand at room temperature or
4°C for one day, and must never be deep-frozen; (2) urine AAP remains
stable at —70°C for one year at least. (3) NAG has to be measured in
fresh urines or in samples stored no more than one month both at —20
and —70°C.
More on tubular enzymuria in diabetics: Measurement of cholinester-
ase activity in IDDM and NIDDM patients. E. Matleucci, L. Pellegrini,
C. Uncini-Manganelli, M. Cecere, F. Ruberti, C. Bertoni, and 0.
Giampietro, Istituto di Clinica Medica II, Scuola di Specializzazione in
Patologia C/mica, Pisa, Italy. Clinical significance and usefulness of
enzymuria in diabetic practice are debated. In 63 insulin-dependent
(IDDM, 31 males, 32 females, aged 16 to 59), 40 non-insulin-dependent
(NIDDM, 22 males, 18 females, aged 44 to 78; l9 on diet alone, 21 on
oral drugs) diabetics and 27 healthy controls (16 males, 11 females, aged
26 to 52) we assayed, in the second morning urine, N-acetyl-/3-D-
glucosaminidase (NAG), a known lysosomal tubular indicator, and
cholinesterase (ChE), of not well defined origin. The total esterase
activity (TotE, ElIman's method) has been divided into aliesterase
(AliE), pseudocholinesterase (PChE) and acetylcholinesterase (AChE)
by means of two inhibitors, eserine and quinidine. Based on the urinary
albumin/creatinine ratio (alb/cr, > or s2 mg/mmol), IDDM were split in
Group 1 (2) and Group 2 (>2). The enclosed Table reports patient
clinical characteristics:
IDDM
Controls
Group 1
All IDDM (alb/cr  2)
n 27 63 36
Age years
BMI kg/rn2
36.9 8.79
23.0 2.79
32.9 11.8 30.5 11.3°
25.3 5.0 25.1 5.7
Duration years 10.9 10.2 8.7 9.5
Insulin lU/kg 0.7 0.1 0.7 0.1
HbAlc % 7.9 1.5 8.2 1.6
Fast gluc mg/dl 195.5 89.8 200.8 77.7
Ur gluc g/24 hr 20.9 28.0 17.9 24.3
Ur alb mg/liter 15.3 104 122.9 409.3 12.0 6.4°
Ur cr mmol/liter 12.5 4.9 10.3 4.8 11.4 5.1
NAG U/liter 4.06 3.00 11.97 11.39° 9.23
TotE U/liter 4.86 2.36 6.62 4.51a 7.08 4.38a
A1iE U/liter 2.67 1.86 5.58 3.77° 6.01 4.18°
PChE U/liter 1.59 1,65 2.26 3.09 1.89 2.23
AChE U/liter 1.00 1.78 0.90 2.00 1.10 2.31
IDDM
Group 2
(alb/cr> 2)
NIDDM
Diet Oral drugs
n 27 19 21
Age years
BMI kg/rn2
37.3 105d
25.8 3.1
59.8 11.8c 65.0 5.7°
27.2 4.9 25.7 2.9
Duration years 13.4 11.6 7.5 7.6 12.5 7.4
Insulin lU/kg 0.8 0.1 — —
HbAlc % 7.6 1.4 7.0 1.1 7.8 1.5
Fast gluc mg/dl 182.3 108.6 136.3 34.0 133.3 42.2
Ur glue g/24 hr 12.0 13.1 5.5 9.7 4.4 7.3
Ur alb mg/liter 145.3 445.6a 35.6 28.9° 35.1 17.2a
Ur cr rnrnol/liter 8.7 4.1 10.8 4.8 9.7 4
NAG U/liter 16.22 1557b.d 7.11 391b 13.02
TotE U/liter 5.76 4.74 4.26 2.90 5.49 4.89
A1iE U/liter 4.77 2.75k' 3.07 3.09 4.18 5.33
PChE U/liter 2.91 4.19 1.49 1.99 2.44 3.37
AChE U/liter 0.54 1.24 0.76 0.81 1.31 1.75
a p < 0.05, b P < 0.01, P < 0.001 diabetics vs. controls; d p<0.05
Group I vs. Group 2.
In IDDM: urinary NAG output is confirmed to be above normal; the
increase precedes microalbuminuria and seems progressive with the
glomerular damage. The urine excretion of TotE and A1iE is signifi-
cantly increased (+36 and + 109% of the controls, respectively), while
PChE and AChE are superimposable to normals. ChE output seems not
influenced by the glomerular leakage of albumin. In NIDDM: urinary
excretion of albumin and NAG is significantly higher than healthy
controls, contrary to cholinesterases which are in the normal limits.
Orally treated NIDDM individuals show a NAG output practically
double than those on diet alone, conceivably addressing to a tubular
overload by hypoglycemic drugs. Although all measured enzymes
concur to disclose a very early tubular dysfunction in diabetes, the
single enzyme seems to be differently affected by the course of diabetic
nephropathy.
Serum levels of procollagen type I C-terminal extension peptide (PICP)
In hemodialysis (HD). S. Mazzaferro, M. Pasquali, P. Ballanti, E.
Bonucci, L. Onorato, S. Perruzza, D. Sardella, and 0. Coen, Renal
Pathophysiology and Hypertension Unit and Department of Human
Biopathology, University "La Sapienza," Rome, Italy. Serum levels of
PICP have been shown to express the osteoblastic rate of collagen
synthesis in patients with slightly increased or reduced bone turnover.
In predialytic secondary hyperparathyroidism, we have described that
serum PICP levels correlate with bone turnover better than osteocalcin
(BGP) and alkaline phosphatase (AP). We evaluated this issue also in
HD, a condition with severe secondary hyperparathyroidism. Serum
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levels of AP, intact PTH (iPTH), BGP and PICP were assayed in 56
patients (48 12 years, HD since 99 50months) who underwent bone
biopsy, for histomorphometric evaluation. Mean humoral values were:
PICP 264 101 ng/ml (n.y. 125 33), iPTH 621 343 pg/mI, BGP 194
117 ng/ml, AP420 401 mU/mI, ObS/BS 13.3 10%, OcS/BS 2.9
1.7%, AjAR 0.868 0.561 t3/s2/day (n.y. 0.49 0.16), BFR/BS 0.432
0.378 3/2/day (n.y. 0.09 0.02), dIS/BS 25.8 15.6%. IPTH, BGP
and AP correlated reciprocally (PTH vs. BGP: r = 0.70; PTH vs. AP r
= 0.64; BGP vs. APr = 0.61; P < 0.001) but not with PICP. A similar
pattern of correlations was found with bone static and dynamic param-
eters (see r values in the table).
ObS/BS OcS/BS BFR/BS AJAR DLS/BS
PTH 0.57 0.56 0.54 0.60 0.60
BGP 0.58 0.56 0.61 0.64 0.71
AP 0.53 0.56 0.67 0.80 0.70
PICP 0.24 0.15 0.24 0.22 0.24
(P< 0.01, if r = 0.34).
Contrary to predialysis, in HD, a condition of sharply increased iPTH
and bone turnover, AP and BGP indicate, better than PICP, the ongoing
calcification process. In this condition, the osteoblastic rate of collagen
synthesis, as expressed by PICP levels, is not coupled with the rate of
osteoid calcification.
Culture of human mesangial cells (MC) in high glucose media modu-
lates cytosolic free calcium ([Ca2i) signaling: Role of protein kinase C.
P. Menè, G.A. Cinotti, and F. Pugliese, Department of Medicine,
Division of Nephrology, University of Rome, Rome, Italy. Extensive
mesangial changes are the hallmark of diabetic glomerulopathy. Mesan-
gial expansion and sclerosis follow an initial phase of hyperfiltration,
mostly due to arteriolar resistance to vasoconstrictors. Since [Ca2]1 is
a major signal for vascular smooth muscle contraction, we studied
whether culture of MC in high glucose affects [Ca2i responses to
vasoconstrictors. After 5 days in 22 m glucose, blunted [Ca2]
responsiveness to various phospholipase C/[Ca2] stimuli [I M angio-
tensin II, 250 15/122 17; I M prostaglandin F2,,, 345 36/174 31;
0.1 iLM arginine vasopressin (AVP), 666 84/281 29, mean SE peak
nM [Ca2j,, 5.5 mM/22 m glucose, respectively; all P < 0.01 vs. 5.5
mMI was detected by ratio fluorometry in fura-2-loaded monolayers.
Inhibition of [Ca2]1 responses was not attributable to an osmotic effect,
since it was not mimicked by 22 mi mannitol (+0.1 /LM AVP 661 52
nM [Ca2'11, NS vs. 5.5 m glucose). While intracellular Ca2 pools,
assessed with ionomycin or 4-Br-A23 187, were unaffected by elevated
glucose, Na/Ca2 exchange was also markedly inhibited (from 520
53 to 278 38 peak flM [Ca2'] upon extracellular Na withdrawal, P <
0.05), thus ruling out both impaired filling of Ca2 stores and enhanced
Ca2 extrusion. Impaired myo-inositol uptake or sorbitol accumulation
were not implicated, since myo-inositol supplementation or the aldose
reductase inhibitor, Alcon 1576, failed to reverse insensitivity to
vasoconstrictors. On the other hand, protein kinase C inhibition by
phorbol esters, staurosporin or H-7 completely reversed the effects of
glucose, thus demonstrating involvement of this signaling pathway.
These data identify a possible cellular mechanism for the altered
glomerular hemodynamics in the early phases of diabetic nephropathy.
Calcitonin and P'f H secretion rate after an oral calcium load in stone
formers with fasting hypercalciuria. P. Messa. G. Mioni, R. Franzon,
and D. Turrin, Divisione di Nefrologia; Islituto di Medicina Nucleare,
Ospedale S. Maria del/a Misericordia Udine, Udine, italy. Previous
studies have given evidence of increased bone resorption (BR) and
reduced sensitivity of PTH to hypocalcemia induced by phosphate
infusion, in stone formers (SF) with fasting hypercalciuria (FH). In
order to evaluate if physiological serum calcium changes induce differ-
ent PTH secretion patterns in FH, we studied 50 SF patients, 25 with
FH and 25 without (NFH). After basal evaluation for nephrolithiasis,
the patients were submitted to a diet with 400 mg of Ca and, after IS
days, the basal study was repeated. Then an OCL (I g of Ca element)
was performed and Ca, phosphate, calcitonin (CT), intact P1'H and
calcitriol were evaluated in serum samples collected before and 2 hours
after the OCL; hydroxyproline (OHP), Ca, phosphate, creatinine in
urine before and 4 hours after the OCL were also measured. The ratio
between the percentage changes of PTH (%dPTH) and CT (%dCT) and
the variation of serum calcium were considered as index of the
hormonal secretion rate.
OHP/
CR
mg/g
PTH CT 1,25
%dPTH/ %dCT/
dCa dCa
%/mg/dlpg/ml
FH
NFH
22.0
111b
14.7
4.0
20.2
12.3"
26.4
10.3
33.7
33"
15.2
18.3
39.6
14
35.2
10.4
—59.8 —12
120b 127
—169.9 79.2
124 139
The results are expressed as mean SD; "P < 0.05, b P < 0.01, ' P
<0.001.
•The OHP/Cr excretion, index of BR, were strictly related to fasting Ca
excretion (C) and inversely related to PTH levels ("). The %dPTH/dCa
were significantly correlated with both fasting Ca/Cr and OHP/Cr
excretion (") and dCT inversely correlated with dOHP after OCL (") In
conclusion: (I) FH is well matched with higher BR index and reduced
PTH levels; (2) A reduced %dPTH changes were evident in FH SF after
physiological sCa variations; (3) CT seems to play a role (compensato-
ry?) in these changes.
Hyperchloremic acidosis and base balance in renal transplant. G.
Mioni, C. Va/lone, R. Franzon, and P. Messa, Division of Nephrology,
City Hospital, Udine, Italy. A-B status and base balance have been
studied in 29 transplant patients without clinical complications and in
metabolic balance. Twenty were treated with cyclosporin A, all with
imuran + cortisone. In the plasma and/or urine, pH, PCO2, TA, NH4,
mono- and divalent ions, PTH, 25 and 1-25 OHD3, OHP, urea and
creatinine were measured. pCI and p.HCO3 mean values were normal
(107 7; 24 3 mmol/liter) but inversely correlated (r2 = 0.54; P =
0.00001). The correlation between pHCO3 and p.Cl+ + PTH + Vit.D
(r2 = 0.62;P= 0.00001) showed a negative preponderant influence of Cl
and PTH on p.HCO3. The TmPi/GFR was reduced (2.31 I mg/dl) and
inversely correlated with PTH (r2 = 0.21; P = 0.003). PCR was 89 3
g/kg day without any correlation with Ca/Cr, OHP/Cr and net acid
excretion (NA). Endogenous H2S04 was neutralized by intestinal base
absorption without bone involvement: H2S04 versus Ca/Cr and OHP/
Cr, P = NS (intestinal base absorption 46 18 mmol/day; H2S04
generation 41 16 mEq/day; NA excretion 13 25 mmol/day (0.2
mEq/Kg day). (I) In renal transplant, plasma A-B status is controlled by
PTH acting in favor of Cl— and against Pi and HCO3 reabsorption. (2)
Endogenous acid generation is neutralized by intestinal base absorp-
tion. (3) The bone is barely involved in A-B control.
Prevalences of microalbuminuria and macrovascular disease (MVD) in
a population of type 11 diabetic patients. F. Modena, P. Faronato, and F.
Antonucci, Servizio di Nefrologia e Dialisi, Servizio di Diabetologia,
Ospedale Civile di Feltre, Feltre, Italy. It has been suggested that
microalbuminuria might predict macrovascular disease in NIDDM. We
analyzed the relationship between the prevalences of microalbuminuna
and MVD in a cross-sectional survey of 225 (100 M, 125 F) NIDDM
patients with normal renal function (mean serum creatinine 91.1 1.8
SEM mol/liter [1.03 0.02 mg/dID followed by the Diabetes Center of
our hospital. We evaluated: age; length of diabetes; urinary albumin
concentration (UAC) (RIA); HBA1c; serum glucose, triglycerides, and
cholesterol; Cockroft and Gault creatinine clearance; arterial blood
pressure; presence of coronary heart disease, cerebral vascular disease,
and peripheral vascular disease. Presence of MVD was determined on
a non-invasive clinical and anamnestic base (symptoms, therapy).
Patients with microalbuminuria (UAC > 20 mg/liter) (27% of all
subjects) significantly differed from those without microalbuminuria
only for higher systolic blood pressure (SBP) levels (154 2.7 vs. 146
1.8 mm Hg, P 0.02) and more frequent use of anti-hypertensive
drugs (64 vs. 50%, P = 0.04). The two groups did not differ for
prevalences of coronary heart disease, cerebral vascular disease or
peripheral vascular disease. Multivariate analysis (logistic regression)
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identified as predictors of microalbuminuria male sex, HbAlc and SBP
levels (standardized regression coefficients [SRC]: 2.1, 2, and 1.9,
respectively). Predictors of peripheral vascular disease were: male sex,
serum glucose and cholesterol levels (SRC: 2.4, 1.9, 1.9); of cerebral
vascular disease: length of diabetes (SRC: 1.7); of coronary heart
disease: age (SRC: 3.4). Microalbuminuria never resulted as a predictor
of MVD. In conclusion, in our population of NIDDM patients the
prevalence of microalbuminuria is not significantly different between
patients with or without MVD; microalbuminuna is associated with
higher systolic blood pressure levels and is not a predictor of MVD.
Association of membranous glomerulonephritls (MGN) with hereditary
partial functional deficiency of the anticoagulant factor protein S. V.
Montinaro, L. Maffione, and F.P. Schena, Chair and Division of
Nephrology, University of Ban, Ban, Italy. Alterations of the coagu-
lation system have been widely reported in nephrotic syndrome. The
hypercoagulative condition can determine arterious and venous throm-
boses. The association of renal vein thrombosis with nephrotic syn-
drome (NS) in MGN has a peculiar pathogenetic relevance. Among the
alterations of the coagulation proteins, there is an increase of plasma
antigenic levels of Protein S and C (which are anticoagulants) during
NS. This report describes a case of MGN associated with a heredo-
familial functional defect of protein S. A 34-year-old male (E.R.)
showed NS followed shortly by thrombophlebitis of femoral-popliteal
vein of left limb. Treatment with steroids and cyclophosphamide did not
affect the NS. On the contrary, a complete remission of NS and partial
remission of proteinuria was obtained with cyclosporine and, subse-
quently, enalapril. A complete study of the coagulation system was
performed during the remission of NS (proteinuria 1 g/24 hr). No
alteration of coagulation tests was observed (PT: 108.3%, ratio 0.97;
aPTT: 30.6", ratio 1.01; fibnnogen 250 mg/dl; thrombin time: 17.3", ratio
0.961; antithrombin III: 98%; a2-antiptasmin: 120%; plasminogen activ-
ity: 88%). Antigenic levels oft-PA and PAl-i (2.1 ng/ml and 0.7 ng/ml,
respectively) and functional activity of PA! and Protein C (5.5 AU/mi
and 75%, respectively) were within normal range. The only abnormality
was a significant reduction of protein S function (42%), although the
antigenic levels were normal (free fraction 75%, total fraction 81%).
This alteration was present in the other four members of the propositus'
family without renal dysfunction. Subsequently, since the discovery of
the protein S defect the patient is being treated with calcium-heparin
(5000 U b.i.d.). Mterward, we observed a further reduction of protein-
uria to normal values. Conclusions: Some hereditary functional deficien-
cies of the coagulative system can have pathogenetic relevance in
idiopathic NS due to MGN.
Effects of chronic i.v. calcitriol (CLT) treatment on some immunolog-
ical functions of hemodialyzed uremic patients (HUP). L. Marsano, E.
Moriero, D. Rolla, A. Faninelli, L. Murgia, F. Indiveri, and G.
Cannella, Divisione di Nefrologia e Dialisi, Ospedale S. Martino,
Dipartimento di Medicina Interna, Universitâ, Genova, Italy. Chronic
HUP suffer from many abnormalities of both humoral and cellular
immunity, which had been attributed to the underlying long-standing
hyperparathyroidism (HPT) and/or to the Vit-D3 deficiency. We report
results of our study on serial measurements of the opsonic activity of
the serum (SOA), the phagocytic activity of PMN (PHA), and the
natural killer activity (NKA) of 10 HUP with relevant signs of second-
ary HPT, before and 3 and 6 months after the start of a therapy with i.v.
CLT (30 ng/kg, thrice weekly). Both PHA and SOA were determined
with a Biolumat luminometer. PHA was assessed by matching the PMN
of the HUP with zymosan opsonized with normal serum, while the SOA
was assessed by matching PMN of healthy subjects with the serum of
the HUP, The NKA was assessed by using Cr51 labeled K562 eryth-
roleukemic cells as a target. Pre-treatment values for SOA [45 cli,
(range 11.6—119)] and NKA [37.5%; (25—51)] were both significantly
lower than those for 10 sex- and age-matched controls (98, 55—124 and
60, 51—71), while PHA was similar. CLT treatment over six months
resulted in a significant P1'H decrease [from 1049 127 (ES) to 410
114 pg/mI; P < 0.004 Wilcoxon test]. During the same period both the
SOA and the NK increased significantly up to values which became no
more distinguishable from those of the normal subjects, while the PHA
remained nearly unvaried. Thus, prolonged CLT treatment reversed to
the normal SOA and NKA functions of HUP. This suggests an
ethiopathogenetic role for secondary HPT and/or Vit-D3 deficiency in
inducing these immunological abnormalities in these subjects.
Kinetic mathematical model of sodium in paired filtration dialysis. A.
Negro, I. Susa, G.P. Sancipniano, G. lacono, T. Fidelio, V. Calitri, R.
Scaizo, A. Serra, M.C. Deabate, and C. Licata, Nephrology Service of
Ciziè, Department of Mathematics, University of Torino, Torino, Italy.
The Authors have studied a mathematical model regarding the kinetic of
sodium in PFD considering a variable volume single pool based on
Fick's laws and on the principle of mass balance. The model has been
formalized by a system of three linear differential equations of the first
order, with coefficients depending on time. The three dynamic vari-
ables, functions of time, were the natnemia of patient, the sodium
concentration in the dialysis fluid compartment and in the blood
compartment of the filter. A method for numerically computating the
solutions of the system has been coded in Fortran language on PC 486.
The model allows us to introduce as input of the program the following
parameters (for each dialysis session): (I) the filter surface, diffusive
and convective section; (2) blood and dialysate priming volume of the
filter; (3) duration of each dialysis session; (4) the blood dialysate and
reinfusate flow; (5) the concentration of sodium in the reinfusion fluid;
(6) the value of natriemia (measured) at the beginning of the treatment;
(7) the target post-dialysis natriemia; (8) the patient weight at the
beginning and at the end of the treatment. The model gives the hourly
profile of sodium in the dialysate that has to be programmed during the
treatment in order to reach the following targets: (1) the target post-
dialysis natriemia; (2) a fast constant hourly removal of sodium during
the treatment; (3) the calculation of sodium balance during each PFD
session; (4) the maintenance of a constant post dialysis pool of sodium.
The system allowed the performance of simulations of sodium kinetics
during PFD, varying the different parameter mentioned above.
Living unrelated kidney transplantation. Experience of 110 cases. R.
Pretagostini, P. Benloco, D. Alfani, M. Rossi, L. Poli, G. Pisani, andR.
Cortesini, II Patologia Chirurgica, University of Rome "La Sapienza,"
Rome, Italy. The number of potential kidney transplant recipients is
steadily rising, due to the increase of patients treated with dialysis and
for the inadequate availability of cadaver grafts (CD). The use of living
unrelated donors as a source for transplantation is still controversial. In
this study, the authors report their experience in this late group of
patients in the cyclosporine era. From January 1983 to December 1992,
593 kidney transplantations were carried out, 226 from living related
donors (LRD) and 110 from living unrelated donors (LURD). In the
LURD group the relationships between donors and recipient were: in 75
cases wife to husband, in 23 cases husband to wife, in 6 cases uncle to
nephew, and in 6 cases cousin to cousin. In living unrelated donor
transplantation all donors underwent the same medical evaluation as
living related donors. They have been also investigated to assure that
their motivation was only based on feelings of love and altruism. All
LURD were ABO matched with negative crossmatch. In 99 cases HLA
A-B compatibility was 0—1 match and in 87 cases HLA Dr compatibility
was 0 match. The average age was 26.8 years in the LRD group, 44.9
years in the LURD group and 32.5 years in the CD group. The statistic
analysis was executed with the y test. The patient and graft survivals
obtained in LURD group were compared with the ones in the LRD and
CD group.
Patient survival Graft survival
9 1 5 9
years year years years
The lower 9 years actuarial patient survival in LURD group can be
related to the elder age of recipients. In conclusion, LURD transplants
can be considered a real alternative to CD transplants for better long
graft survival. Therefore, this procedure must be considered safe and
N. 1 5
Population cases year years
LRD 196 95.3% 94.5% 94.5%
P = 0.0001
LURD 110 89.8% 82.9% 69.1%
P = 0.0261
CD 244 89.6% 87.9% 80.2%
89.5% 74% 66.6%
P = NS
86.8% 72.3% 60.3%
P = 0.0039
78.4% 66.8% 43.8%
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effective and should be encouraged to increase the donor pool and to
reduce the waiting list for kidney transplantation.
Report of the Italian multicenter study on Alport syndrome. A.
Renieri, M. Seri, L. Gaili, M. Bruttini, M. Dc Marchi (Biologia
Molecolare, Pal. Le Scotte, Siena), M. Meroni, G. Bait mi, A. Sessa
(Vimercare), T. Faraggiana, L. Masseila, G. Rizzoni (Roma), P.
Riegier (Boizano), B. Basolo, R. Coppo, G. Monga, A. Vercelione
(Torino), F. Ajmar, C. Borrone, D. Lamperi, R. Gatti, R. Gusmano
(Genova), G, Banfi, M. Giani (Milano), E. Imbasciati (Lodi), C. Danesino
(Pavia), M. Mileti (Crema), F. Fasciolo, F. Scolari (Brescia), A. Lupo, A.
Turco (Verona), R. Tenconi (Padova), M. V. Pellanda (Bassano), L.
Peratoner (Trieste), Mignani (Rimini), M. Savi (Parma), G. Lavoratti, M.
Saivadori (Firenze), A. Antoneili (Lucca), R. Polio (Pisa), N. Di Paoio, W.
Livi (Siena), M. Ragaioio (Ascoli Piceno), Pecoraro (Napoli, S. Schia-
vano (Casarano), C. Manno (Ban), M. Buemi (Messina), Italy. The locus
of X-linked Alport syndrome is the COL4A5 gene, which encodes the
a5(IV) chain. In 69 kindreds, mutation screening was performed by
Southern blotting and non-isotopic single-strand conformation polymor-
phism analysis on 11/51 exons of the COL4A5 gene. A molecular defect
was identified in 13 kindreds and a correlation with the clinical phenotype
has been attempted:
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Membrane permeability and dialytic adequacy in patients on CAPD.
M. Querques, A. Pappani, A. Tappi, D.A. Procaccini, and P. Strippoli,
Divisions of Nephroiogy and Dialysis, Foggia, S. Severo, and Taranto,
Italy. During 83 studies on permeability, which were made on 52
patients on CAPD, based on the values of peritoneal clearances of
creatinine, three kinds of membrane were observed: high, medium, and
low permeability to solutes. The differences among the regression lines
between the value of clearances of creatinine, the UF and the log n of
dwell-time were statistically significant (P < 0.01). With the same
amount of liters/day infused, the dialytic (excluding the residual renal
function) Kr/V of urea was significantly higher in patients with high
permeability of the membrane. By considering that the t12 of the rrf was
1035 303 days, the necessary dialytic dose, after such a time, to keep
the Kr/V levels stable, then became so high that it required the use of
semiautomatic machines that should perform part of the exchanges
during the night. At present, the levels of dialitic adequacy suggested in
the literature could provoke in younger patients the marks of under-
dialysis. Patients with low permeability of the membrane may be
adequately dialyzed only if there is a satisfactory rrf. When such a
function decreases, transferring the patients to a new treatment will be
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necessary. Patients with high permeability of the membrane may use, in
order to have a satisfactory hydric balance, a combined treatment (HD
+ CAPD), once the rrf ends. Patients with medium permeability, as
time goes on, have to get more dialytic treatment, in order to fulfill the
loss of rrf. The levels of dialytic adequacy should be increased in
younger patients (Car 70 liters/week/l.73 BSA) to avoid underdialysis
syndrome. Such measures could fulfill the discrepancy among indices of
dialytic adequacy and the clinical rehabilitation of the patients.
Interferon alpha-2C (rINF-a-2c) treatment in hemodialysis patients
chronic carriers of HCV infection (HCV-RNA-I-): Preliminary results. P.
Riegler, B. Giacon, W. Passler, P. Eder, P. Koenig, W. Vogel, F.
Umlauft, and W. Huber, Department of Nephrology and Dialysis,
Bolzano; Department of Medicine, Brunico; and Department of Inter-
nal Medicine and Laboratory for Molecular Biology, University of
Innsbruck, Innsbruck, Austria. Seroprevalence of anti-HCV among
Italian dialysis patients is 32.2%. HCV-RNA tested by polymerase
chain reaction is an indicator of ongoing HCV infection, even in the
absence of pathologic liver values. Interferon (rINF) is the treatment of
choice in reducing activity in chronic viral hepatic infection. Methods:
15 (7 F, 8 M) chronic HCV-RNA+ hemodialysis patients, mean age 57
15 years (mean dialytic age 61.5 months, 21—210) were treated for 16
weeks with 5 million rINF-alpha-2c subcutaneously three times weekly
after each dialysis. They underwent a constant clinical and biochemical
control for 8 more weeks. Every fourteen days we checked AST, ALT,
gammaGT, LDH, Hb, prothrombin time, platelets, thrombocytes,
Ieukocytes and HCV-RNA. Results: Eleven patients out of the original
15 concluded the treatment. Four patients stopped the treatment
because of sepsis (3 cases), neurological side effects (I case) and lack of
compliance. During the 16 weeks of treatment, thrombocytes, leuko-
cytes and neutrophils decreased significantly (P < 0.003 and P < 0.001)
dating from the 2nd and 3rd and remained low until the 6th/8th week and
grew later on. ALT 34.5 23.24 U/liter at the beginning of treatment
showed no significant reduction. Hemoglobin decreased significantly
also (P < 0.001) and needed an increase of EPO medication. Forty
percent (6/15) of our patients became HCV-RNA by the 2nd week of
treatment, and within the 6th week 53% were HCV-RNA. Two weeks
after treatment was completed 47% of patients were still HCV-RNA-,
and after 6 more weeks 53% (8/15) were HCV-RNA-. Three out of our
8 HCV-RNA- patients at the 24th week stopped their treatment due to
side effects, respectively, at the 2nd and 10th week. Seven percent
(1/15) of our patients never became HCV-RNA-. The most common
side effects occurred during the first weeks of treatment; they were of
grade I and II: fever, fatigue, nausea/vomiting, diarrhea. Conclusion:
Detection of hepatitis C virus RNA in serum is useful for evaluating the
antiviral effect of interferon. Early responders to the treatment seemed
to remain HCV-RNA-; late responders relapsed more frequently. Our
results with rINF treatment of chronic hepatitis C infection among
hemodialysis patients are similar to those of non-hemodialysis patients.
Different patterns of response to INF treatment seem to be recogniz-
able, perhaps depending on virus strain or the immune response of the
host.
Serum iPTH and t,25(OH)2D3 behaviors after single calcitriol oral
pulse in CAPD patients. D. Romanini, A. Gazo, R. Beliazzi, M.
Sanlagostino, M. Nai, and A. de Vincenzi, Nephrology and Dialysis
Unit, Vigevano, Italy. We evaluated the biohumoral effects of a single
oral calcitriol pulse (0.05 sg/kg) in 8 CAPD patients with mild HPT
(baseline PTH 247 + 60 pg/mI), previously treated with 3.5 mEq/liter
calcium dialysate, oral calcitrol 0.25—0.5 mg, and CaCO3 2—4 g daily.
Serum levels of iPTH, l,25(OH)2D3, total Ca, and P prior
(—24/—12 hours) and after (6/12/24/36/48/96/7 gg/l 1 ggIl4 gg) bolus were
determined. l,25(OH)2D3 baseline levels were 10 + 3.02 pg/mI, and 6
hours after bolus showed serum levels peak (85 + 36 pg/mI), returning
at 96 hours below the normal values. Bolus significantly decreased PTH
serum levels from 12 to 36 hours (153 + 101 pg/mI at 24 hr) P < 0.01.
Total Ca and Ca levels had a peak at 24 hours, respectively 9.5 + 0.3
mg/dl and 1.34 + 0.04 mmol/liter and presented an inverse correlation to
iPTH values. Ca x P reached maximum values at 24 hours after bolus,
but always <60. Oral calcitriol pulse (0.05 pg/kg) may be safely used in
the treatment of second degree HPT in CAPD patients. Different
weekly schedules of therapy with single or double pulses and 3.5 or 2.5
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mEq/liter calcium dialysate may be proposed in mild and/or severe
HPT.
Effects of immunosuppressive drugs on neutrophil chemotaxis. M.
Scavuzzo, R. Di Stefano, M. Carmellini, G. Rizzo, P. Rindi, A.
Fagiolini, and F. Mosca, Institute of General and Experimental Sur-
gery, University of Pisa; Nephrologic Division, S. Chiara Hospital,
Pisa, Italy. Neutrophils have long been recognized to be important cells
in the immune system; in fact, they are the first cells to arrive at an
inflammation site. The effect of most immunosuppressive drugs upon
neutrophils is not known. We therefore studied how drugs interfere
with neutrophil migration capability. In vitro we tested the chemotaxis,
in Boyden chamber, of 2 hour cultured human neutrophils from healthy
donors with dexamethasone (lO.-6 M), azathioprine (1 tg/m1) or cyclo-
sporine (3 g/ml) alone in Boyden chambers in response to a range of s.
Cerevisie activated pool of human serum. Results indicated that Aza
and Dcx inhibited neutrophil chemotaxis, while Csa had no effect at the
above dosage. We then designed experiments to analyze dose-response
curves of Dex (range lO_h1_lO_6 M), Aza (range 15—1000 ng/ml), and
Csa (7.5—3000 ng/ml). Results indicated the minimum concentration of
each drug which gave the maximum inhibition of chemotaxis: 37% and
42%, respectively for Aza and Dex; Csa-cultured neutrophils did not
show reduced migration responsiveness but even apparent enhance-
ment. We then screened the inhibitory effect of drugs in combination as
shown in the table:
Drug combinations Doses % inhibition
Csa + Aza 15 ng/ml + 30 ng/ml 35
Csa + Dcx 15 ng/ml + 10_b M 41
Aza + Dcx 30 ng/ml + l0'° M 45
Csa + Aza + Dcx 15 ng/ml + 30 ng/ml + 10-10 M 50
To assess how immunosuppressive modalities affect local inflammatory
reactions in vivo, we tested neutrophils from stable kidney transplant
patients treated with different therapeutic regimens. Therapies which
mostly affected neutrophil mobility were azathioprine + steroids and
triple, as expected. Surprisingly, neutrophils isolated in different occa-
sions, from patients on Csa monotherapy, did show inhibition of
chemotaxis. Selective action on neutrophil function might explain a
difference in controlling graft rejection or in preserving host defense
mechanisms by different immunosuppressive drugs.
ATPase-dependent Na/K pump and Na/K cotransport activation
In the erythrocyte membranes of a patient affected by myopathy due to
liquorice abuse. A.M. Stanzial, C. Menini, S. Friso, 0. Olivieri, N.
Tessitore, A. Bartoloni, and R. Corrocher, Institute of Medical Pathol-
ogy, Chair of Internal Medicine, Nephrology Division, Institute of
Anaesthesiology and Reanimation, University of Verona, Verona,
Italy. A 60 year-old man was hospitalized for hypertension (200/105 mm
Hg), cramps, asthenia, polydipsia and poliuna, The anamnesis showed
a liquorice abuse (glycyrrhizin 48 mg/day) for some years and therapy
with chlorthalidone (12.5 mg/day) during one month before. The bio-
chemical parameters relieved a hypochioremic metabolic alkalosis (pH
7.57; HC03 60 mEq/liter; Cl- 74 mEq/liter), a hypokalemia (1.5
mEq/liter), an increase of creatine phosphokinase 17800 U/liter, myo-
globin 3500 zg/liter, isosthenuria and prolonged QT. Plasma renin was
reduced (0.10 ng/ml/hr) and plasma aldosterone was undetectable.
Electrolytic and clinic situation was normalized with hydratation and
potassium supplement within three days; on the contrary, until after
two months, blood hypertension and renin inhibition persisted, whereas
plasma aldosterone returned to normal long before. The observation of
an increase of the ATPase-dependent Na/K pump (15,168 mmol/liter
cells/hr. normal values 5.30 1.33) and of cotransport Na/K (Na
cot 2,309 mmol/liter cells/hour, vs. 0.836 0.264; K cot 2,6 mmol/liter
cells/hour, vs. 1.131 0.324) observed on the patient erythrocyte
membranes, with normal cationic intraglobular concentrations (Na
24.56 mEq/kg Hb, vs. 22.75 3.19; K 308.7 mEq/kg Hb, vs. 293.44
18.11) suggests that liquorice abuse, producing a pseudohyperaldoste-
ronism, may cause ionic unbalances so crucially important as to alter
the cationic trans-membrane transports. The plasma aldosterone nor-
malization revealed that the patient was affected by Liddle's syndrome.
Erythrocytic dysmorphism and aluminemia in HD uremic patients.
P.F. Zatta, P. Moracchiello, and G. Bazzato, Centro CNR-Metallo-
proteine, Dipartimenw di Biologia dell' Universitâ diPadova; Divisione
Nefrologia, Ospedale "Umberto I," Mestre-Venezia, Italy. The
present study reports scan electron microscopy (SEM) and NMR 31P
data on erythrocytes from 10 uremic patients on HD with plasma
aluminum concentration from 50 to 100 sg/liter. With these concentra-
tions an erythrocytic dysmorphism metallo-dependence was observed
(see figure). Preliminary experiments carried out using NMR 31P using
erythrocytic membranes from the same patients showed a characteristic
"chemical shift." This fact can indicate an interaction between the
metal and membrane phospholipids that could justify the erythrocytic
dysmorphism observed by SEM and better defined by image analysis.
These data, even if preliminary, could give indications on the potenti-
ality of using the erythrocytic dysmorphism as a way to diagnose Al(llI)
accumulation in uremic patients.
Altered renal handling of endothelin I in essential hypertension. C.
Zoccali, D. Leonardis, S. Parlongo, M. Romeo, M. Postorino, and F.
Mallamaci, Division of Nephrology and CNR Centre of Clinical Phys-
iology, Reggio Calabria Italy. Endothelin has autocrine and paracrine
effects of primary importance for the local control of the circulation,
influences renal Na handling, and interferes with the major arterial
pressor control systems. To investigate the role of this vasoactive
peptide in human hypertension, we measured the plasma concentration
and the urinary excretion of endothelin I (ET) in 21 untreated essential
hypertensives (EH) with normal renal function (GFR 70—181 mI/mm), in
11 hypertensive patients with primary renal disease (RH) and renal
insufficiency (GFR 2—77 mI/mm), and in a group of 8 normotensive
subjects (NS) with normal renal function matched for age and sex. ET
I was measured by a radioimmunoassay employing an antibody which
does not cross react with ET 3. Plasma ET was markedly higher (P <
0.01) in essential hypertensives (2.25 0.29 SEM pg/mi) than in
normotensive control subjects (1.01 0.23 pg/mI), but significantly less
(P < 0.01) than in hypertensive patients with renal disease (5.7 0.9
pg/mi). ET was directly related with diastolic pressure both in essential
hypertensives (r = 0.43, P < 0.05) and in renal hypertensives (r = 0.72,P = 0.02). ET excretion was almost identical in the three groups (EH:
138 12 ng/24 hr, RH: 182 22 ng/24 hr, NS: 133 26 ng/24 hr).
However, when the results were expressed in terms of ET clearance per
unit of functioning renal mass, the behavior of essential hypertensives
differed (P < 0.01) from that of renal hypertensives because the
CIET/GFR ratio was markedly reduced (0.5 0.1) in the first group and
substantially raised in the second group (3.4 1.4) in comparison with
normotensive control subjects (1.63 1.0). Since the CIE.p'GFR ratio
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should be I if all filtered ET is excreted without any secretion or
reuptake by the tubules, this finding indicates that ET is synthesized by
remnant nephrons in renal hypertensives, while it is actually broken
down by the kidney in essential hypertensives. The data, while con-
firming a close link between circulating ET and arterial pressure in
primary and secondary forms of hypertension, point to a peculiar
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alteration in the renal handling of this peptide in patients with essential
hypertension. The enhanced renal breakdown of endothelin may be a
counter-regulatory response aimed at attenuating its (primary or sec-
ondary) effects on the kidney and/or may be involved in the derange-
ments of tubular Na reabsorption and of renal circulation of essential
hypertensives.
